1. Pink Sheet

Pandemic Perspectives: Safety Monitoring Boost For COVID Vaccines Creating ‘A New Normal’ For Pharmacovigilance

 
• By Sarah Karlin-Smith

Pink Sheet infographic puts together the many new and existing safety systems being used to track and evaluate COVID-19 vaccine adverse events. There are early signs the vaccination effort has led to heightened public attention on medication safety that may be here to stay.

puzzle pieces with Pandemic Perspectives logo
• Source: Shutterstock

COVID-19 vaccines are being subject to heightened safety scrutiny because of the speed of their development and regulatory clearance under the emergency use authorization pathway and because of the unusual amount of public attention on the rollout, given the vaccines potential to dampen a global pandemic. A third unique element is the evolving nature of the virus the vaccines are targeting.

Pandemic Perspectives

One year on from the World Health Organization declaring COVID-19 a global pandemic on 11 March 2020, editors across Informa Pharma Intelligence publications are taking a closer look at its

To address the unusual challenge, the US has upped its safety efforts, creating two new pharmacovigilance systems for COVID-19 vaccines and bolstering another

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

US FDA Adcomm To Consider If Genentech’s Columvi Study Generalizable To US

 
• By Sue Sutter

Patients from Asia saw a differential treatment effect versus non-Asian regions in the Phase III multiregional study, with an adverse survival trend seen in the latter group, the FDA said about the lymphoma drug.

Califf In Conversation: ‘Decimated’ US FDA Teams Endanger Innovation

 
• By Barnaby Pickering

Pink Sheet sister publication In Vivo spoke to the former FDA commissioner about the recent layoffs and their impact on vaccine and other product development.

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.